Translating cancer 'omics' to improved outcomes

Genome Research

Volumn 22, Issue 2, 2012, Pages 188-195

  Vucic, Emily A ^a,b   Thu, Kelsie L ^a   Robison, Keith ^c   Rybaczyk, Leszek A ^d   Chari, Raj ^a,b,e   Alvarez, Carlos E ^d   Lam, Wan L ^a,b  

^a BRITISH COLUMBIA CANCER RESEARCH CENTRE   (Canada)

^b UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^c Warp Drive Bio ^*  (United States)

^d THE RESEARCH INSTITUTE AT NATIONWIDE CHILDREN S HOSPITAL   (United States)

^e HARVARD MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CANCER GENETICS; CANCER PATIENT; GENETIC HETEROGENEITY; GENOME; GENOME ANALYSIS; GENOMICS; HISTOLOGY; OVERALL SURVIVAL; PRIORITY JOURNAL; REVIEW;

ANIMALS; DISEASE MODELS, ANIMAL; EARLY DETECTION OF CANCER; GENETIC ASSOCIATION STUDIES; GENOMICS; HUMANS; MOLECULAR TARGETED THERAPY; MUTATION; NEOPLASMS; PROGNOSIS; PROTEOMICS; SIGNAL TRANSDUCTION; TRANSLATIONAL MEDICAL RESEARCH; TUMOR MARKERS, BIOLOGICAL;

EID: 84856544035     PISSN: 10889051     EISSN: 15495469     Source Type: Journal    
DOI: 10.1101/gr.124354.111     Document Type: Review

References (102)

1. Aberle DR, Adams AM, Berg CD, Black WC, Clapp JD, Fagerstrom RM, Gareen IF, Gatsonis C, Marcus PM, Sicks JD. 2011. Reduced lung-cancer mortality with low-dose computed tomographic screening. N Engl J Med 365: 395-409.
2. Ahn MJ, Won HH, Lee J, Lee ST, Sun JM, Park YH, Ahn JS, Kwon OJ, Kim H, Shim YM, et al. 2011. The 18p11.22 locus is associated with never smoker non-small cell lung cancer susceptibility in Korean populations. Hum Genet doi: 10.1007/s00439-011-1080-z.
3. Allegra CJ, Jessup JM, Somerfield MR, Hamilton SR, Hammond EH, Hayes DF, McAllister PK, Morton RF, Schilsky RL. 2009. American Society of Clinical Oncology provisional clinical opinion: Testing for KRAS gene mutations in patients with metastatic colorectal carcinoma to predict response to anti-epidermal growth factor receptor monoclonal antibody therapy. J Clin Oncol 27: 2091-2096.
4. Bernstein BE, Stamatoyannopoulos JA, Costello JF, Ren B, Milosavljevic A, Meissner A, Kellis M, Marra MA, Beaudet AL, Ecker JR, et al. 2010. The NIH Roadmap Epigenomics Mapping Consortium. Nat Biotechnol 28: 1045-1048.
5. Bignell GR, Santarius T, Pole JC, Butler AP, Perry J, Pleasance E, Greenman C, Menzies A, Taylor S, Edkins S, et al. 2007. Architectures of somatic genomic rearrangement in human cancer amplicons at sequence-level resolution. Genome Res 17: 1296-1303. (Pubitemid 47360904)
6. Boca SM, Kinzler KW, Velculescu VE, Vogelstein B, Parmigiani G. 2010. Patient-oriented gene set analysis for cancer mutation data. Genome Biol 11: R112. doi: 10.1186/gb-2010-11-11-r112.
7. Boyko AR, Quignon P, Li L, Schoenebeck JJ, Degenhardt JD, Lohmueller KE, Zhao K, Brisbin A, Parker HG, vonHoldt BM, et al. 2010. A simple genetic architecture underlies morphological variation in dogs. PLoS Biol 8: e1000451. doi: 10.1371/journal.pbio.1000451.
8. Bozic I, Antal T, Ohtsuki H, Carter H, Kim D, Chen S, Karchin R, Kinzler KW, Vogelstein B, Nowak MA. 2010. Accumulation of driver and passenger mutations during tumor progression. Proc Natl Acad Sci 107: 18545-18550.
9. Cancer Genome Atlas Research Network. 2008. Comprehensive genomic characterization defines human glioblastoma genes and core pathways. Nature 455: 1061-1068.
10. Chapman MA, Lawrence MS, Keats JJ, Cibulskis K, Sougnez C, Schinzel AC, Harview CL, Brunet JP, Ahmann GJ, Adli M, et al. 2011. Initial genome sequencing and analysis of multiple myeloma. Nature 471: 467-472.
11. Chari R, Coe BP, Vucic EA, Lockwood WW, Lam WL. 2010a. An integrative multi-dimensional genetic and epigenetic strategy to identify aberrant genes and pathways in cancer. BMC Syst Biol 4: 67.
12. Chari R, Thu KL, Wilson IM, Lockwood WW, Lonergan KM, Coe BP, Malloff CA, Gazdar AF, Lam S, Garnis C, et al. 2010b. Integrating the multiple dimensions of genomic and epigenomic landscapes of cancer. Cancer Metastasis Rev 29: 73-93.
13. Chen WK, Swartz JD, Rush LJ, Alvarez CE. 2009. Mapping DNA structural variation in dogs. Genome Res 19: 500-509.
14. Chin L, Andersen JN, Futreal PA. 2011. Cancer genomics: From discovery science to personalized medicine. Nat Med 17: 297-303.
15. Church GM. 2005. The personal genome project. Mol Syst Biol 1: 2005.0030. doi: 10.1038/msb4100040.
16. Dasgupta S, Soudry E, Mukhopadhyay N, Shao C, Yee J, Lam S, Lam W, Zhang W, Gazdar AF, Fisher PB, et al. 2011. Mitochondrial DNA mutations in respiratory complex-I in never-smoker lung cancer patients contribute to lung cancer progression and associated with EGFR gene mutation. J Cell Physiol doi: 10.1002/jcp.22980.
17. Daskalos A, Nikolaidis G, Xinarianos G, Savvari P, Cassidy A, Zakopoulou R, Kotsinas A, Gorgoulis V, Field JK, Liloglou T. 2009. Hypomethylation of retrotransposable elements correlates with genomic instability in non-small cell lung cancer. Int J Cancer 124: 81-87.
18. De S, Michor F. 2011. DNA secondary structures and epigenetic determinants of cancer genome evolution. Nat Struct Mol Biol 18: 950-955.
19. Ding L, Getz G, Wheeler DA, Mardis ER, McLellan MD, Cibulskis K, Sougnez C, Greulich H, Muzny DM, Morgan MB, et al. 2008. Somatic mutations affect key pathways in lung adenocarcinoma. Nature 455:1069-1075.
20. Druker BJ. 2008. Translation of the Philadelphia chromosome into therapy for CML. Blood 112: 4808-4817.
21. Druker BJ, Guilhot F, O'Brien SG, Gathmann I, Kantarjian H, Gattermann N, Deininger MW, Silver RT, Goldman JM, Stone RM, et al. 2006. Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia. N Engl J Med 355: 2408-2417. (Pubitemid 44903745)
22. Dunbar AJ, Gondek LP, O'Keefe CL, Makishima H, Rataul MS, Szpurka H, Sekeres MA, Wang XF, McDevitt MA, Maciejewski JP. 2008. 250K single nucleotide polymorphism array karyotyping identifies acquired uniparental disomy and homozygous mutations, including novel missense substitutions of c-Cbl, in myeloid malignancies. Cancer Res 68: 10349-10357.
23. DuPage M, Dooley AL, Jacks T. 2009. Conditional mouse lung cancer models using adenoviral or lentiviral delivery of Cre recombinase. Nat Protoc 4: 1064-1072.
24. Eden A, Gaudet F, Waghmare A, Jaenisch R. 2003. Chromosomal instability and tumors promoted by DNA hypomethylation. Science 300: 455. (Pubitemid 36444319)
25. Engelman JA, Janne PA. 2008. Mechanisms of acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in non-small cell lung cancer. Clin Cancer Res 14: 2895-2899.
26. Etzioni R, Urban N, Ramsey S, McIntosh M, Schwartz S, Reid B, Radich J, Anderson G, Hartwell L. 2003. The case for early detection. Nat Rev Cancer 3: 243-252. (Pubitemid 37328860)
27. Firestone B. 2010. The challenge of selecting the 'right' in vivo oncology pharmacology model. Curr Opin Pharmacol 10: 391-396.
28. Fischer A, Greenman C, Mustonen V. 2011. Germline fitness based scoring of cancer mutations. Genetics 188: 383-393.
29. Flaherty KT, Puzanov I, Kim KB, Ribas A, McArthur GA, Sosman JA, O'Dwyer PJ, Lee RJ, Grippo JF, Nolop K, et al. 2010. Inhibition of mutated, activated BRAF in metastatic melanoma. N Engl J Med 363: 809-819.
30. Fojo T, Parkinson DR. 2010. Biologically targeted cancer therapy and marginal benefits: Are we making too much of too little or are we achieving too little by giving too much? Clin Cancer Res 16: 5972-5980.
31. Gandhi J, Zhang J, Xie Y, Soh J, Shigematsu H, Zhang W, Yamamoto H, Peyton M, Girard L, Lockwood WW, et al. 2009. Alterations in genes of the EGFR signaling pathway and their relationship to EGFR tyrosine kinase inhibitor sensitivity in lung cancer cell lines. PLoS ONE 4: e4576. doi: 10.1371/journal.pone.0004576.
32. Gerber DE, Minna JD. 2010. ALK inhibition for non-small cell lung cancer: From discovery to therapy in record time. Cancer Cell 18: 548-551.
33. Gondek LP, Dunbar AJ, Szpurka H, McDevitt MA, Maciejewski JP. 2007. SNP array karyotyping allows for the detection of uniparental disomy and cryptic chromosomal abnormalities in MDS/MPD-U and MPD. PLoS ONE 2: e1225. doi: 10.1371/journal.pone.0001225.
34. Greenman C, Wooster R, Futreal PA, Stratton MR, Easton DF. 2006. Statistical analysis of pathogenicity of somatic mutations in cancer. Genetics 173: 2187-2198. (Pubitemid 44285695)
35. Haber DA, Gray NS, Baselga J. 2011. The evolving war on cancer. Cell 145: 19-24.
36. Halpern MT, Gillespie BW, Warner KE. 1993. Patterns of absolute risk of lung cancer mortality in former smokers. J Natl Cancer Inst 85: 457-464. (Pubitemid 23084090)
37. Hampson R. 1997. Selection for genome instability by DNA damage in human cells: Unstable microsatellites and their consequences for tumourigenesis. Radiat Oncol Investig 5: 111-114. (Pubitemid 27357907)
38. Hoffmann S. 2011. Computational analysis of high throughput sequencing data. Methods Mol Biol 719: 199-217.
39. Hood L, Heath JR, Phelps ME, Lin B. 2004. Systems biology and new technologies enable predictive and preventative medicine. Science 306: 640-643. (Pubitemid 39440903)
40. Hudis CA. 2007. Trastuzumab - mechanism of action and use in clinical practice. N Engl J Med 357: 39-51. (Pubitemid 47026733)
41. Hudson TJ, Anderson W, Artez A, Barker AD, Bell C, Bernabe RR, Bhan MK, Calvo F, Eerola I, Gerhard DS, et al. 2010. International network of cancer genome projects. Nature 464: 993-998.
42. Igarashi S, Suzuki H, Niinuma T, Shimizu H, Nojima M, Iwaki H, Nobuoka T, Nishida T, Miyazaki Y, Takamaru H, et al. 2010. A novel correlation between LINE-1 hypomethylation and the malignancy of gastrointestinal stromal tumors. Clin Cancer Res 16: 5114-5123.
43. Jones SJ, Laskin J, Li YY, Griffith OL, An J, Bilenky M, Butterfield YS, Cezard T, Chuah E, Corbett R, et al. 2010. Evolution of an adenocarcinoma in response to selection by targeted kinase inhibitors. Genome Biol 11: R82. doi: 10.1186/gb-2010-11-8-r82.
44. Kane MF, Loda M, Gaida GM, Lipman J, Mishra R, Goldman H, Jessup JM, Kolodner R. 1997. Methylation of the hMLH1 promoter correlates with lack of expression of hMLH1 in sporadic colon tumors and mismatch repair-defective human tumor cell lines. Cancer Res 57: 808-811. (Pubitemid 27097998)
45. Kanehisa M, Goto S, Furumichi M, Tanabe M, Hirakawa M. 2010. KEGG for representation and analysis of molecular networks involving diseases and drugs. Nucleic Acids Res 38: D355-D360.
46. Karapetis CS, Khambata-Ford S, Jonker DJ, O'Callaghan CJ, Tu D, Tebbutt NC, Simes RJ, Chalchal H, Shapiro JD, Robitaille S, et al. 2008. K-ras mutations and benefit from cetuximab in advanced colorectal cancer. N Engl J Med 359: 1757-1765.
47. Keedy VL, Temin S, Somerfield MR, Beasley MB, Johnson DH, McShane LM, Milton DT, Strawn JR, Wakelee HA, Giaccone G. 2011. American Society of Clinical Oncology Provisional Clinical Opinion: Epidermal growth factor receptor (EGFR) mutation testing for patients with advanced non-small-cell lung cancer considering first-line EGFR tyrosine kinase inhibitor therapy. J Clin Oncol 29: 2121-2127.
48. Kwak EL, Bang YJ, Camidge DR, Shaw AT, Solomon B, Maki RG, Ou SH, Dezube BJ, Janne PA, Costa DB, et al. 2010. Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer. N Engl J Med 363: 1693-1703.
49. Laurent-Puig P, Cayre A, Manceau G, Buc E, Bachet JB, Lecomte T, Rougier P, Lievre A, Landi B, Boige V, et al. 2009. Analysis of PTEN, BRAF, and EGFR status in determining benefit from cetuximab therapy in wild-type KRAS metastatic colon cancer. J Clin Oncol 27: 5924-5930.
50. Lee W, Jiang Z, Liu J, Haverty PM, Guan Y, Stinson J, Yue P, Zhang Y, Pant KP, Bhatt D, et al. 2010. The mutation spectrum revealed by paired genome sequences from a lung cancer patient. Nature 465: 473-477.
51. Link DC, Schuettpelz LG, Shen D, Wang J, Walter MJ, Kulkarni S, Payton JE, Ivanovich J, Goodfellow PJ, Le Beau M, et al. 2011. Identification of a novel TP53 cancer susceptibility mutation through whole-genome sequencing of a patient with therapy-related AML. JAMA 305: 1568-1576.
52. Liotta LA, Petricoin E. 2011. Cancer biomarkers: Closer to delivering on their promise. Cancer Cell 20: 279-280.
53. Lunshof JE, Bobe J, Aach J, Angrist M, Thakuria JV, Vorhaus DB, Hoehe MR, Church GM. 2010. Personal genomes in progress: From the human genome project to the personal genome project. Dialogues Clin Neurosci 12: 47-60.
54. Lussier YA, Chen JL. 2011. The emergence of genome-based drug repositioning. Sci Transl Med 3: 96ps35. doi: 10.1126/scitranslmed.3001512.
55. Lynch TJ, Bell DW, Sordella R, Gurubhagavatula S, Okimoto RA, Brannigan BW, Harris PL, Haserlat SM, Supko JG, Haluska FG, et al. 2004. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med 350: 2129-2139. (Pubitemid 38637993)
56. Modrek B, Ge L, Pandita A, Lin E, Mohan S, Yue P, Guerrero S, Lin WM, Pham T, Modrusan Z, et al. 2009. Oncogenic activating mutations are associated with local copy gain. Mol Cancer Res 7: 1244-1252.
57. Mort M, Evani US, Krishnan VG, Kamati KK, Baenziger PH, Bagchi A, Peters BJ, Sathyesh R, Li B, Sun Y, et al. 2010. In silico functional profiling of human disease-associated and polymorphic amino acid substitutions. Hum Mutat 31: 335-346.
58. Nowell PC, Hungerford DA. 1961. Chromosome studies in human leukemia. II. Chronic granulocytic leukemia. J Natl Cancer Inst 27: 1013-1035.
59. Oakman C, Santarpia L, Di Leo A. 2010. Breast cancer assessment tools and optimizing adjuvant therapy. Nat Rev Clin Oncol 7: 725-732.
60. Offit K. 2011. Personalized medicine: New genomics, old lessons. Hum Genet 130: 3-14.
61. Paez JG, Janne PA, Lee JC, Tracy S, Greulich H, Gabriel S, Herman P, Kaye FJ, Lindeman N, Boggon TJ, et al. 2004. EGFR mutations in lung cancer: Correlation with clinical response to gefitinib therapy. Science 304: 1497-1500. (Pubitemid 38720929)
62. Pallis A, Briasoulis E, Linardou H, Papadimitriou C, Bafaloukos D, Kosmidis P, Murray S. 2011. Mechanisms of resistance to epidermal growth factor receptor tyrosine kinase inhibitors in patientswith advanced non-small-cell lung cancer: clinical and molecular considerations. Curr Med Chem 18: 1613-1628.
63. Pao W, Chmielecki J. 2010. Rational, biologically based treatment of EGFR-mutant non-small-cell lung cancer. Nat Rev Cancer 10: 760-774.
64. Papaetis GS, Syrigos KN. 2010. Targeted therapy for gastrointestinal stromal tumors: Current status and future perspectives. Cancer Metastasis Rev 29: 151-170.
65. Park JH, Han SW, Oh DY, Im SA, Jeong SY, Park KJ, Kim TY, Bang YJ, Park JG. 2011. Analysis of KRAS, BRAF, PTEN, IGF1R, EGFR intron 1 CA status in both primary tumors and paired metastases in determining benefit from cetuximab therapy in colon cancer. Cancer Chemother Pharmacol 68: 1045-1055.
66. Parker HG, Shearin AL, Ostrander EA. 2010. Man's best friend becomes biology's best in show: Genome analyses in the domestic dog. Annu Rev Genet 44: 309-336.
67. Pasche B, Absher D. 2011. Whole-genome sequencing: A step closer to personalized medicine. JAMA 305: 1596-1597.
68. Perez-Losada J, Castellanos-Martin A, Mao JH. 2011. Cancer evolution and individual susceptibility. Integr Biol (Camb) 3: 316-328.
69. Peto R, Darby S, Deo H, Silcocks P, Whitley E, Doll R. 2000. Smoking, smoking cessation, and lung cancer in the UK since 1950: Combination of national statistics with two case-control studies. BMJ 321: 323-329. (Pubitemid 30496873)
70. Philip VM, Sokoloff G, Ackert-Bicknell CL, Striz M, Branstetter L, Beckmann MA, Spence JS, Jackson BL, Galloway LD, Barker P, et al. 2011. Genetic analysis in the Collaborative Cross breeding population. Genome Res 21: 1223-1238.
71. Pleasance ED, Stephens PJ, O'Meara S, McBride DJ, Meynert A, Jones D, Lin ML, Beare D, Lau KW, Greenman C, et al. 2010. A small-cell lung cancer genome with complex signatures of tobacco exposure. Nature 463: 184-190.
72. Politi K, Pao W. 2011. How genetically engineered mouse tumor models provide insights into human cancers. J Clin Oncol 29: 2273-2281.
73. Politi K, Zakowski MF, Fan PD, Schonfeld EA, Pao W, Varmus HE. 2006. Lung adenocarcinomas induced in mice by mutant EGF receptors found in human lung cancers respond to a tyrosine kinase inhibitor or to downregulation of the receptors. Genes Dev 20: 1496-1510. (Pubitemid 43830656)
74. Poste G. 2011. Bring on the biomarkers. Nature 469: 156-157.
75. Poulikakos PI, Rosen N. 2011. Mutant BRAF melanomas-dependence and resistance. Cancer Cell 19: 11-15.
76. Prat A, Perou CM. 2011. Deconstructing the molecular portraits of breast cancer. Mol Oncol 5: 5-23.
77. Radivojac P, Baenziger PH, Kann MG, Mort ME, Hahn MW, Mooney SD. 2008. Gain and loss of phosphorylation sites in human cancer. Bioinformatics 24: i241-i247.
78. Rizwana R, Hahn PJ. 1999. CpG methylation reduces genomic instability. J Cell Sci 112: 4513-4519. (Pubitemid 30034801)
79. Rizzo S, Bronte G, Fanale D, Corsini L, Silvestris N, Santini D, Gulotta G, Bazan V, Gebbia N, Fulfaro F, et al. 2010. Prognostic vs predictive molecular biomarkers in colorectal cancer: Is KRAS and BRAF wild type status required for anti-EGFR therapy? Cancer Treat Rev (Suppl 3) 36: S56-S61.
80. Robison K. 2010. Application of second-generation sequencing to cancer genomics. Brief Bioinform 11: 524-534.
81. Rowell JL, McCarthy DO, Alvarez CE. 2011. Dog models of naturally occurring cancer. Trends Mol Med 17: 380-388.
82. Sawyers CL. 2008. The cancer biomarker problem. Nature 452: 548-552. (Pubitemid 351483368)
83. Segditsas S, Rowan AJ, Howarth K, Jones A, Leedham S, Wright NA, Gorman P, Chambers W, Domingo E, Roylance RR, et al. 2009. APC and the three-hit hypothesis. Oncogene 28: 146-155.
84. Sengupta S, Chakrabarti S, Roy A, Panda CK, Roychoudhury S. 2007. Inactivation of human mutL homolog 1 and mutS homolog 2 genes in head and neck squamous cell carcinoma tumors and leukoplakia samples by promoter hypermethylation and its relation with microsatellite instability phenotype. Cancer 109: 703-712. (Pubitemid 46233231)
85. Shima K, Nosho K, Baba Y, Cantor M, Meyerhardt JA, Giovannucci EL, Fuchs CS, Ogino S. 2011. Prognostic significance of CDKN2A (p16) promoter methylation and loss of expression in 902 colorectal cancers: Cohort study and literature review. Int J Cancer 128: 1080-1094.
86. Soda M, Choi YL, Enomoto M, Takada S, Yamashita Y, Ishikawa S, Fujiwara S, Watanabe H, Kurashina K, Hatanaka H, et al. 2007. Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer. Nature 448: 561-566. (Pubitemid 47206930)
87. Soh J, Okumura N, Lockwood WW, Yamamoto H, Shigematsu H, Zhang W, Chari R, Shames DS, Tang X, MacAulay C, et al. 2009. Oncogene mutations, copy number gains and mutant allele specific imbalance (MASI) frequently occur together in tumor cells. PLoS ONE 4: e7464. doi: 10.1371/journal.pone.0007464.
88. Stephens PJ, McBride DJ, Lin ML, Varela I, Pleasance ED, Simpson JT, Stebbings LA, Leroy C, Edkins S, Mudie LJ, et al. 2009. Complex landscapes of somatic rearrangement in human breast cancer genomes. Nature 462: 1005-1010.
89. Stricker T, Catenacci DV, Seiwert TY. 2011. Molecular profiling of cancer - the future of personalized cancer medicine: A primer on cancer biology and the tools necessary to bring molecular testing to the clinic. Semin Oncol 38: 173-185.
90. Swanton C, Burrell RA, Futreal PA. 2011. Breast cancer genome heterogeneity: A challenge to personalised medicine? Breast Cancer Res 13: 104.
91. Tawfik HM, El-Maqsoud NM, Hak BH, El-Sherbiny YM. 2011. Head and neck squamous cell carcinoma: Mismatch repair immunohistochemistry and promoter hypermethylation of hMLH1 gene. Am J Otolaryngol 32: 528-536.
92. Tong L, Spitz MR, Fueger JJ, Amos CA. 1996. Lung carcinoma in former smokers. Cancer 78: 1004-1010. (Pubitemid 26284865)
93. van Zandwijk N, Mathy A, Boerrigter L, Ruijter H, Tielen I, de Jong D, Baas P, Burgers S, Nederlof P. 2007. EGFR and KRAS mutations as criteria for treatment with tyrosine kinase inhibitors: Retro- and prospective observations in non-small-cell lung cancer. Ann Oncol 18: 99-103. (Pubitemid 46152507)
94. Vasavi M, Kiran V, Ravishankar B, Prabhakar B, Ahuja YR, Hasan Q. 2010. Microsatellite instability analysis and its correlation with hMLH1 repair gene hypermethylation status in esophageal pathologies including cancers. Cancer Biomark 7: 1-10.
95. Verhaak RG, Hoadley KA, Purdom E, Wang V, Qi Y, Wilkerson MD, Miller CR, Ding L, Golub T, Mesirov JP, et al. 2010. Integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1. Cancer Cell 17: 98-110.
96. Vidal M, Cusick ME, Barabasi AL. 2011. Interactome networks and human disease. Cell 144: 986-998.
97. Wang K, Lee I, Carlson G, Hood L, Galas D. 2010. Systems biology and the discovery of diagnostic biomarkers. Dis Markers 28: 199-207.
98. Weitzel JN, Blazer KR, Macdonald DJ, Culver JO, Offit K. 2011. Genetics, genomics, and cancer risk assessment: State of the art and future directions in the era of personalized medicine. CA Cancer J Clin doi: 10.3322/caac.20128.
99. Welch JS, Westervelt P, Ding L, Larson DE, Klco JM, Kulkarni S, Wallis J, Chen K, Payton JE, Fulton RS, et al. 2011. Use of whole-genome sequencing to diagnose a cryptic fusion oncogene. JAMA 305: 1577-1584.
100. Yamamoto G, Nannya Y, Kato M, Sanada M, Levine RL, Kawamata N, Hangaishi A, Kurokawa M, Chiba S, Gilliland DG, et al. 2007. Highly sensitive method for genomewide detection of allelic composition in nonpaired, primary tumor specimens by use of affymetrix single-nucleotide-polymorphism genotyping microarrays. Am J Hum Genet 81: 114-126. (Pubitemid 47001161)
101. Youn A, Simon R. 2011. Identifying cancer driver genes in tumor genome sequencing studies. Bioinformatics 27: 175-181.
102. Zhou Y, Rideout WM III, Zi T, Bressel A, Reddypalli S, Rancourt R, Woo JK, Horner JW, Chin L, Chiu MI, et al. 2010. Chimeric mouse tumor models reveal differences in pathway activation between ERBB family- and KRAS-dependent lung adenocarcinomas. Nat Biotechnol 28: 71-78.